HIGHLIGHTS
- who: Other uses and colleagues from the (UNIVERSITY) have published the article: This Article appeared in journal published by Elsevier, in the Journal: (JOURNAL)
- what: Part of these discrepancies can be explained by the fact that the trials assessing the efficacy of pirfenidone have been designed with lung function as the primary end point, whereas in a disease like IPF the reduction of mortality should be seen as the main goal of treatment.
SUMMARY
An update of that same systematic review, published in 2010,4 did not identify any new additional . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.